Boehringer Ingelheim and Microsoft launched a collaboration to develop AI-powered “digital patient twins” intended to simulate disease progression and treatment response for clinical trials. The project will explore how such models could support synthetic or hybrid control groups, with the aim of accelerating evidence generation and improving trial design. Boehringer described the initiative as exploratory and tied to robust scientific validation and regulatory approvals. The partners pointed to broader momentum in trial-focused AI and the use of similar approaches in government-backed programs. For biopharma, the partnership signals growing interest in AI models that reduce control-group patient burdens while maintaining inferential credibility—an area where regulators’ requirements remain a key gating factor.